SCLERO.ORG is retiring 4-24-2021. Thank you for the memories! You'll still find us in the Wayback Machine, and we'll carry your stories in our hearts forever.
Scleroderma Newsroom
ISN News Manager: Jo Frowde
Media Stories
Autoimmune Archive
We maintain news archives for the most recent 3 years.
2020: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2021 - 2020 - 2019 - 2018

October 2020 Autoimmune News

The Burden of Neurosarcoidosis: Essential Approaches to Early Diagnosis and Treatment. This publication provides an approach to screening, diagnosis, disease activity discernment, and pharmacological as well as nonpharmacological treatment interventions. PubMed, Semin Respir Crit Care Med, 2020 Oct;41(5):641-651. (Also see Sarcoidosis)

Risk of malignancy with non-TNFi biologic or tofacitinib therapy in rheumatoid arthritis: A meta-analysis of observational studies. Among RA patients, a small statistically significant increase in developing cancer was observed for abatacept exposure. Seminars in Arthritis and Rheumatism, 09/03/2020. (Also see Biologic Agents and Treatments for Rheumatoid Arthritis)

Unmet needs in patients with moderate-to-severe plaque psoriasis treated with methotrexate (MTX) in real world practice: FirST study. The study identified unmet needs in moderate-to-severe plaque psoriasis patients treated with MTX. PubMed, J Dermatolog Treat, 2020 Sep 8;1-10. (Also see Psoriasis and Psoriatic Arthritis)

The Role of the IL-23/IL-17 Pathway in the Pathogenesis of Spondyloarthritis In this review, we summarize the current knowledge of the pathomechanism by focusing on the IL-23/IL-17 pathway. PubMed, Int J Mol Sci, 2020 Sep 3;21(17):E6401. (Also see Psoriasis and Psoriatic Arthritis and Interleukins)

Risk of hearing loss (HL) in patients with fibromyalgia (FM): A nationwide population-based retrospective cohort study. Our findings support the notion that FM influences HL and is in line with the hypothesis that the FM mechanism is related to a central nervous system abnormality in sensory processing. PubMed, PLoS One, 2020 Sep 3;15(9):e0238502. (Also see Fibromyalgia)

Efficacy of pregabalin (PGB) as a monotherapy versus combined pregabalin and milnacipran (MLN) in the management of fibromyalgia. The combined therapy of PGB with MLN did not demonstrate superiority over the monotherapy of PGB. PubMed, Int J Rheum Dis, 09/04/2020. (Also see Treatments for Fibromyalgia)

Analysis of the analgesic effects of tricyclic antidepressants on neuropathic pain, diabetic neuropathic pain, and fibromyalgia in rat models. Para-sciatic injection of amitriptyline at different concentrations has analgesic effects on neuropathic pain, diabetic neuropathic pain and fibromyalgia in rat models. PubMed, Saudi J Biol Sci, 2020 Sep;27(9):2485-2490. (Also see Treatments for Fibromyalgia)

Serum Homocysteine Levels and Microalbuminuria (MAU) in Patient with Systemic Lupus Erythematosus (SLE). The current results found a correlation between serum homocysteine and MAU in SLE patients. PubMed, Clin Lab, 2020 Sep 1;66(9). (Also see Causes of Lupus)

Systemic lupus erythematosus; stroke and myocardial infarction (MI) risk: a systematic review and meta-analysis. Overall, patients with SLE were identified to have a twofold to threefold higher risk of stroke and MI. PubMed, Clin Lab, RMD Open, 2020 Sep;6(2):e001247. (Also see Symptoms and Complications of Lupus)

Evaluation of Mental Health Factors among People with Systemic Lupus Erythematosus (SLE) during the SARS-CoV-2 Pandemic. The mental health of patients with SLE in the times of the SARS-CoV-2 pandemic is not only an extremely important medical problem but also a social one and must require special attention. PubMed, J Clin Med, 2020 Sep 5;9(9):E2872. (Also see Systemic Lupus Erythematosus and Depression)

Go to Autoimmune News: September 2020

SCLERO.ORG was the world's leading nonprofit for trustworthy research, support, education and awareness for scleroderma and related illnesses from 1998 to 2021. It was a grassroots movement from the original Scleroderma from A to Z web site, which was founded by Shelley Ensz. We were a 501(c)(3) U.S.-based public charitable foundation. We closed this web site and our nonprofit agency in April 2021.

International Scleroderma Network (ISN)